Insider Trading Alert - MACK, GWRE And CCOI Traded By Insiders

Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer or Stephanie Link.

Yesterday, Nov. 18, 2014, 121 U.S. common stocks issued filings of shares being bought or sold by insiders. The transactions ranged in value from $235.29 to $1,686,187,500.00.

Highlighted Stocks Traded by Insiders:

Merrimack Pharmaceuticals (MACK) - FREE Research Report

Porter Michael E, who is Director at Merrimack Pharmaceuticals, bought 5,000 shares at $8.29 on Nov. 18, 2014. Following this transaction, the Director owned 613,255 shares meaning that the stake was boosted by 0.82% with the 5,000-share transaction.

The shares most recently traded at $9.14, up $0.85, or 9.3% since the insider transaction. Historical insider transactions for Merrimack Pharmaceuticals go as follows:

  • 4-Week # shares bought: 40,000
  • 12-Week # shares bought: 40,000
  • 24-Week # shares bought: 72,390

The average volume for Merrimack Pharmaceuticals has been 2.2 million shares per day over the past 30 days. Merrimack Pharmaceuticals has a market cap of $912.7 million and is part of the health care sector and drugs industry. Shares are up 67.7% year-to-date as of the close of trading on Tuesday.

Merrimack Pharmaceuticals, Inc., a biopharmaceutical company, is engaged in discovering, developing, and preparing to commercialize medicines paired with companion diagnostics for the treatment of cancer primarily in the United States. Currently, there are 3 analysts who rate Merrimack Pharmaceuticals a buy, no analysts rate it a sell, and none rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on MACK - FREE

TheStreet Quant Ratings rates Merrimack Pharmaceuticals as a sell. The area that we feel has been the company's primary weakness has been its unimpressive growth in net income. Get the full Merrimack Pharmaceuticals Ratings Report from TheStreet Quant Ratings now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

Guidewire Software (GWRE) - FREE Research Report

Conway Craig, who is Director at Guidewire Software, sold 24,000 shares at $50.57 on Nov. 18, 2014. Following this transaction, the Director owned 35,472 shares meaning that the stake was reduced by 40.36% with the 24,000-share transaction.

The shares most recently traded at $49.38, down $1.19, or 2.4% since the insider transaction. Historical insider transactions for Guidewire Software go as follows:

  • 4-Week # shares bought: 5,000
  • 4-Week # shares sold: 30,000
  • 12-Week # shares bought: 5,000
  • 12-Week # shares sold: 154,826
  • 24-Week # shares bought: 5,000
  • 24-Week # shares sold: 286,818

The average volume for Guidewire Software has been 519,100 shares per day over the past 30 days. Guidewire Software has a market cap of $3.5 billion and is part of the technology sector and computer software & services industry. Shares are up 2.06% year-to-date as of the close of trading on Tuesday.

Guidewire Software, Inc. provides software products for property and casualty (P&C) insurers. It offers an integrated suite of software applications that address the core processes, such as underwriting and policy administration, claims management, and billing. The company has a P/E ratio of 238.9. Currently, there are 4 analysts who rate Guidewire Software a buy, no analysts rate it a sell, and 1 rates it a hold.

Exclusive Offer: Get the latest Stock Analysis on GWRE - FREE

TheStreet Quant Ratings rates Guidewire Software as a hold. The company's strengths can be seen in multiple areas, such as its increase in net income, robust revenue growth and largely solid financial position with reasonable debt levels by most measures. However, as a counter to these strengths, we find that the company's return on equity has been disappointing. Get the full Guidewire Software Ratings Report from TheStreet Quant Ratings now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

Cogent Communications Holdings (CCOI) - FREE Research Report

Kilmer Henry W, who is VP of IP Engineering at Cogent Communications Holdings, sold 1,250 shares at $35.78 on Nov. 18, 2014. Following this transaction, the VP of IP Engineering owned 49,000 shares meaning that the stake was reduced by 2.49% with the 1,250-share transaction.

The shares most recently traded at $35.13, down $0.65, or 1.85% since the insider transaction. Historical insider transactions for Cogent Communications Holdings go as follows:

  • 4-Week # shares sold: 7,000
  • 12-Week # shares sold: 21,750
  • 24-Week # shares sold: 46,000

The average volume for Cogent Communications Holdings has been 366,500 shares per day over the past 30 days. Cogent Communications Holdings has a market cap of $1.7 billion and is part of the technology sector and telecommunications industry. Shares are down 13.02% year-to-date as of the close of trading on Tuesday.

Cogent Communications Holdings, Inc., through its subsidiaries, provides high-speed Internet access and Internet protocol communications service. The stock currently has a dividend yield of 3.46%. The company has a P/E ratio of 31.4. Currently, there are 5 analysts who rate Cogent Communications Holdings a buy, 2 analysts rate it a sell, and 3 rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on CCOI - FREE

TheStreet Quant Ratings rates Cogent Communications Holdings as a buy. The company's strengths can be seen in multiple areas, such as its revenue growth, notable return on equity, good cash flow from operations and expanding profit margins. We feel these strengths outweigh the fact that the company has had lackluster performance in the stock itself. Get the full Cogent Communications Holdings Ratings Report from TheStreet Quant Ratings now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

null

More from Markets

Global Stocks Ease as Investors Focus on Dollar, Oil, Italy After US-China Truce

Global Stocks Ease as Investors Focus on Dollar, Oil, Italy After US-China Truce

Replay: Jim Cramer on Tariffs, the Market Rally, Caterpillar and Micron

Replay: Jim Cramer on Tariffs, the Market Rally, Caterpillar and Micron

Video: When Planning for Retirement, Don't Underestimate Your Life Span

Video: When Planning for Retirement, Don't Underestimate Your Life Span

Video: Here's What May Come Next for Theranos Founder and CEO Elizabeth Holmes

Video: Here's What May Come Next for Theranos Founder and CEO Elizabeth Holmes

Charlie Gasparino Says GE Is Reportedly Looking to Slash Its Dividend Again

Charlie Gasparino Says GE Is Reportedly Looking to Slash Its Dividend Again